Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002360:Carubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D012075:Remission, Spontaneous; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D003520:Cyclophosphamide; D002360:Carubicin